+ 12,3 % bei Geron (902213) Was ist los? o. T.

Geron Corporation Announces Proposed Public Offering of Common Stock and Warrants

finance.yahoo.com/news/...nces-proposed-public-200310558.html

Geron Announces Plans for Imetelstat Phase 3 Clinical Trial in Myelofibrosis and Other Updates

finance.yahoo.com/news/...ans-imetelstat-phase-200110179.html

150 Mio. $ Offering

Was für eine Verwässerung!

ir.geron.com/investors/press-releases/...arrants/default.aspx

seekingalpha.com/news/...essure-after-pricing-equity-offering

dafür hält sich der Kurs aber verdammt gut.

nochmals richtig Volumen.

KOL Events vom 17.06.20.
ir.geron.com/investors/events/

Hier die Präsentation dazu:
s24.q4cdn.com/668523011/files/...L-Event-06.17.2020-FINAL.pdf

Geron Receives Positive Opinion from the EMA Committee for Orphan Medicinal Products for Orphan Drug Designation in the European Union for Imetelstat to Treat Myelodysplastic Syndromes

finance.yahoo.com/news/...positive-opinion-ema-123010504.html

Zahlen für Q2/20

• keine Umsätze
  
• Verlust 16 Mio. $
  
• Cash 265 Mio. $
  
• MK 546 Mio. $
  

"Based on current planning assumptions, the Company expects such funds to be sufficient for its operations into the second half of 2022 when top-line results for the IMerge Phase 3 clinical trial in lower risk MDS and completion of patient enrollment for the planned Phase 3 clinical trial in refractory MF are expected."

ir.geron.com/investors/press-releases/...-Events/default.aspx

www.marketbeat.com/stocks/NASDAQ/GERN/institutional-ownership/

www.marketbeat.com/stocks/NASDAQ/GERN/price-target/

Enrollment Milestone in IMerge Phase 3 Clinical Trial in Lower Risk MDS

IMerge Phase 3 enrollment completion expected in second quarter of 2021

Top-line results expected in second half of 2022

ir.geron.com/investors/press-releases/...Risk-MDS/default.aspx

wir sind mal wieder über $2.
Was mir ein bisschen Sorgen macht sind die 310.47M outstanding shares.

www.analystratings.com/articles/...-dna-sciences-nasdaq-apdn/

News vom 17.06.21

Geron Announces Publication of IMbark Phase 2 Data in Journal of Clinical Oncology

…The publication highlights the clinical benefits observed in the study, including symptom response and overall survival, as well as the evidence of disease-modifying activity from biomarker and bone marrow fibrosis assessments.


finance.yahoo.com/news/...ication-imbark-phase-203000620.html

Brutales Volumen am Freitag! Durchschnitt sind ~7 Mio. Aktien, gehandelt wurden ~346 Mio. Aktien! Wird das die nächste Orphazyme? Ich glaube es zwar nicht, aber man sollte die Aktie und das Volumen definitiv im Auge behalten in der nächsten Woche.

Zahlen für Q2/21

• keine Umsätze
  
• Verlust 30 Mio. $
  
• Cash 239 Mio. $
  
• MK 405 Mio. $
  

These financial resources, combined with expected future non-dilutive funding under the current debt facility, are now expected to fund operations through the end of the first quarter of 2023.

“We are pleased with the achievement of 91% of the planned enrollment in IMerge Phase 3 and expect the trial to be fully enrolled in the fourth quarter of 2021. In addition, the expected timing for top-line results in IMerge Phase 3 has been accelerated by three months to the first quarter of 2023,”

ir.geron.com/investors/press-releases/...of-2023/default.aspx

Publication of Analyses Comparing Real World Data to IMbark Phase 2 in Annals of Hematology

•Analyses Suggest Survival Benefit Associated with Imetelstat Treatment in Comparison to Best Available Therapy

•Overall Survival is Primary Endpoint for Ongoing Phase 3 Clinical Trial in Refractory MF


ir.geron.com/investors/press-releases/...atology/default.aspx